Vasculitis Market
Vasculitis Market Size, Share & Trends Analysis By Type (Large Vessels, Medium Vessels and Small Vessels), By Diagnosis Tests (Blood Test, Urine Test, Imaging Test and Other), By Therapeutic Class (Corticosteroids, Immunosuppressants and Biologics) and By End Users (Hospitals and Clinics, Diagnosis Center, Research Institutes and Other), Forecast Period (2026-2035)
Industry Overview
Vasculitis market was valued at $293.2 million in 2025 and is projected to reach $446.2 million by 2035, growing at a CAGR of 4.4% during the forecast Period (2026-2035). The market is driven by the increasing prevalence of the disease, improved diagnosis, and the development of advanced biologic and targeted therapies. Key factors contributing to market growth include the growing emphasis on personalized medicine, rising investment in research and development, and a greater focus on improving patient outcomes through innovative treatments like Janus kinase (JAK) inhibitors.
Market Dynamics
Rising Prevalence of Autoimmune and Inflammatory Disorders
One of the primary drivers of the global vasculitis market is the increasing prevalence of autoimmune and inflammatory diseases worldwide. Conditions such as Giant Cell Arteritis, Takayasu Arteritis, and ANCA-associated vasculitis are being diagnosed more frequently due to growing awareness and improved access to healthcare services. The aging global population—particularly in North America, Europe, and parts of Asia has significantly contributed to this rise, as elderly individuals are more susceptible to several forms of vasculitis. This demographic shift, combined with heightened surveillance and enhanced clinical recognition, continues to generate steady demand for diagnosis and long-term treatment.
Advancements in Diagnostic Imaging and Biomarker Technologies
Rapid improvements in diagnostic technologies form another key driver of market growth. High-resolution imaging modalities such as PET-CT, MRI angiography, Doppler ultrasound, and CT angiography have revolutionized the ability to detect inflammation in blood vessels with greater accuracy and at earlier stages. Additionally, advancements in serological biomarkers, including ANCA testing and emerging molecular assays, are enabling more precise disease classification and monitoring. These technological advancements significantly reduce diagnostic delays, enhance treatment outcomes, and increase the volume of patients entering care pathways ultimately boosting market expansion.
Growing Adoption of Biologics and Targeted Immunotherapies
The expanding use of biologic drugs and targeted immunotherapies is another major driver accelerating the growth of the vasculitis market. Innovations such as interleukin-6 inhibitors, B-cell–depleting agents, TNF-alpha blockers, and complement inhibitors have transformed the treatment landscape, offering improved efficacy and reduced relapse rates compared to conventional corticosteroids alone. Pharmaceutical companies are increasingly investing in clinical trials for novel biologics, combination therapies, and precision-based treatment approaches. As these advanced therapies gain regulatory approvals and become more widely adopted, they significantly enhance market revenues and strengthen long-term growth prospects across global healthcare systems.
Market Segmentation
- Based on the component, the market is segmented into hardware, and software.
- Based on the technology, the market is segmented into semi & fully immersive, and non-immersive.
- Based on the portability, the market is segmented into head-mounted displays (HMD) , gesture-tracking devices (GTD), and projectors & display walls (PDW).
- Based on the application, the market is segmented into gaming & entertainment, healthcare, aerospace & defense, commercial, enterprise / training / simulation, and others.
Corticosteroids Segment to Grow at a Considerable Market Share
The corticosteroids segment under the therapeutic class category leads the market with the largest share. Corticosteroids remain the primary and most widely prescribed treatment for nearly all forms of vasculitis, including large-, medium-, and small-vessel diseases, due to their rapid anti-inflammatory action, ability to control acute flare-ups, and broad therapeutic effectiveness across different patient groups. Their longstanding clinical acceptance, cost-effectiveness, and inclusion as first-line therapy in global clinical guidelines significantly strengthen their dominance. Additionally, the high prevalence of autoimmune-related vasculitis cases, increased diagnosis through advanced testing, and the growing patient population seeking early treatment drive the demand for corticosteroids. Hospitals and clinics predominantly utilize these drugs as the initial therapeutic approach, further boosting their usage. Despite the rising adoption of biologics and advanced immunosuppressants, corticosteroids continue to maintain the largest market share due to their accessibility, proven efficacy, and essential role in treatment protocols, positioning them as the leading segment in the Global Vasculitis Market.
Large Vessels:A Key Segment in Market Growth
Large vessel vasculitides, primarily represented by Giant Cell Arteritis (GCA) and Takayasu Arteritis (TAK) have been witnessing rising prevalence, especially among aging populations in North America and Europe, where the burden of chronic inflammatory diseases continues to climb. This segment benefits from strong clinical awareness and improved diagnostic accuracy, driven by the increasing use of advanced imaging tests such as CT, MRI, PET scans, and Doppler ultrasonography, which are now essential for large-vessel inflammation assessment.
Furthermore, major pharmaceutical innovations, including the expanding use of biologics such as IL-6 inhibitors, corticosteroids, and emerging targeted immunotherapies, are particularly prominent in the treatment of large vessel vasculitis, further boosting market revenues. The segment is also supported by high healthcare spending, early diagnosis initiatives, and greater involvement of specialty centers. Due to its severe clinical impact, higher diagnosis rates, strong drug pipeline, and frequent treatment monitoring requirements, the Large Vessels segment maintains the largest market share and is expected to remain the dominant driver of growth throughout the forecast period.
Regional Outlook
The global vasculitis market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global vasculitis market with a major share, driven by its advanced healthcare infrastructure, high diagnostic capabilities, and strong presence of leading pharmaceutical companies involved in autoimmune and inflammatory disease research. The country reports a comparatively higher detection rate of vasculitis types such as Giant Cell Arteritis and ANCA-associated vasculitis due to greater clinical awareness, routine screening among high-risk populations, and widespread access to sophisticated diagnostic tools, including PET, CT, MRI, and advanced serological testing. The US also benefits from substantial investments in immunology and rare disease research, supported by organizations such as the NIH, which continuously fund clinical trials for novel biologics and targeted therapies.
Additionally, the availability of well-established reimbursement frameworks and insurance coverage for biologic treatments enhances patient access to high-cost therapies, further expanding market revenues. The presence of major players such as Amgen, Roche, Novartis, and GSK with strong pipelines for vasculitis therapeutics also cements the country’s leadership position. With a growing elderly population, high healthcare spending, early adoption of innovative treatments, and continuous advancements in specialty care, the United States is expected to maintain its dominant share in the global vasculitis market throughout the forecast period.
Market Players Outlook
The major companies operating in the global vasculitis market include Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline (GSK) plc, Novartis AG, and Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Developments
- In October 2024, Vasculitis Foundation established a new support group aimed at young adults aged 18 to 30 who are living with vasculitis, a series of autoimmune conditions characterized by inflammation of blood vessels. The group is designed to foster connections among its members, allowing them to share experiences, seek advice, express concerns, celebrate milestones, and offer mutual support. This initiative is part of the foundation's broader effort, which includes various online support groups for patients and families, as well as specific groups for parents, teenagers, and individuals with eosinophilic granulomatosis with polyangiitis, the rarest form of AAV.
- In April 2024, PARADISE launched a personalised prediction tool for individuals with Vasculitis, featuring an informational video series titled '10 things to know about Vasculitis.' The videos cater to various audiences, including patients, healthcare professionals, and researchers, and are available in nine languages. This initiative was developed by the Patient Advisory Group in the PARADISE project, which aims to incorporate patient perspectives into research. The PARADISE project, focused on personalising relapse risk management in autoimmune diseases, is a collaboration between the ADAPT Centre and Trinity Translational Medicine Institute, funded by ERAPerMed and coordinated by Mark Little from Trinity College Dublin.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global vasculitis market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Vasculitis Market Sales Analysis – Type | Diagnosis Tests | Therapeutic Class | End Users ($ Million)
- Vasculitis Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Vasculitis Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Vasculitis Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Vasculitis Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Vasculitis Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Vasculitis Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Vasculitis Market Revenue and Share by Manufacturers
- Vasculitis Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Bristol-Myers Squibb Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Hoffmann-La Roche Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- GlaxoSmithKline (GSK) plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Bristol-Myers Squibb Company
- Key Company Analysis
- Global Vasculitis Market Sales Analysis by Type ($ Million)
- Large Vessels
- Medium Vessels
- Small Vessels
- Global Vasculitis Market Sales Analysis by Diagnosis Tests ($ Million)
- Blood Test
- Urine Test
- Imaging Test
- Other
- Global Vasculitis Market Sales Analysis by Therapeutic Class ($ Million)
- Corticosteroids
- Immunosuppressants
- Biologics
- Global Vasculitis Market Sales Analysis by End Users ($ Million)
- Hospitals and Clinics
- Diagnosis Center
- Research Institutess
- Others
- Regional Analysis
- North American Vasculitis Market Sales Analysis – Type | Diagnosis Tests | Therapeutic Class | End Users | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Vasculitis Market Sales Analysis – Type | Diagnosis Tests | Therapeutic Class | End Users | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Vasculitis Market Sales Analysis – Type | Diagnosis Tests | Therapeutic Class | End Users | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Vasculitis Market Sales Analysis – Type | Diagnosis Tests | Therapeutic Class | End Users | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amneal Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol-Myers Squibb Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- ChemoCentryx, Inc. (now part of Amgen)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Daiichi Sankyo Co. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc (GSK)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- InflaRx N.V.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Staidson BioPharma Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- UCB SA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Vifor Pharma Management Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Vasculitis Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global Large Vessels Vasculitis Market Research And Analysis By Region, 2025–2035 ($ Million)
3. Global Medium Vessels Vasculitis Market Research And Analysis By Region, 2025–2035 ($ Million)
4. Global Small Vessels Vasculitis Market Research And Analysis By Region, 2025–2035 ($ Million)
5. Global Vasculitis Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
6. Global Vasculitis Blood Test Market Research And Analysis By Region, 2025–2035 ($ Million)
7. Global Vasculitis Urine Test Market Research And Analysis By Region, 2025–2035 ($ Million)
8. Global Vasculitis Imaging Test Market Research And Analysis By Region, 2025–2035 ($ Million)
9. Global Vasculitis Other Diagnosis Tests Market Research And Analysis By Region, 2025–2035 ($ Million)
10. Global Vasculitis Market Research and Analysis by Therapeutic Class, 2025–2035 ($ Million)
11. Global Corticosteroids Vasculitis Market Research And Analysis By Region, 2025–2035 ($ Million)
12. Global Immunosuppressants Vasculitis Market Research And Analysis By Region, 2025–2035 ($ Million)
13. Global Biologics Vasculitis Market Research And Analysis By Region, 2025–2035 ($ Million)
14. Global Vasculitis Market Research and Analysis by End Users, 2025–2035 ($ Million)
15. Global Vasculitis Hospitals and Clinics Market Research And Analysis By Region, 2025–2035 ($ Million)
16. Global Vasculitis Diagnosis Center Market Research And Analysis By Region, 2025–2035 ($ Million)
17. Global Vasculitis Research Institutes Market Research And Analysis By Region, 2025–2035 ($ Million)
18. Global Vasculitis In Other End Users Market Research And Analysis By Region, 2025–2035 ($ Million)
19. Global Vasculitis Market Research and Analysis by Region, 2025–2035 ($ Million)
20. North American Vasculitis Market Research and Analysis by Country, 2025–2035 ($ Million)
21. North American Vasculitis Market Research and Analysis by Type, 2025–2035 ($ Million)
22. North American Vasculitis Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
23. North American Vasculitis Market Research and Analysis by Therapeutic Class, 2025–2035 ($ Million)
24. North American Vasculitis Market Research and Analysis by End Users, 2025–2035 ($ Million)
25. European Vasculitis Market Research and Analysis by Country, 2025–2035 ($ Million)
26. European Vasculitis Market Research and Analysis by Type, 2025–2035 ($ Million)
27. European Vasculitis Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
28. European Vasculitis Market Research and Analysis by Therapeutic Class , 2025–2035 ($ Million)
29. European Vasculitis Market Research and Analysis by End Users, 2025–2035 ($ Million)
30. Asia-Pacific Vasculitis Market Research and Analysis by Country, 2025–2035 ($ Million)
31. Asia-Pacific Vasculitis Market Research and Analysis by Type, 2025–2035 ($ Million)
32. Asia-Pacific Vasculitis Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
33. Asia-Pacific Vasculitis Market Research and Analysis by Therapeutic Class, 2025–2035 ($ Million)
34. Asia-Pacific Vasculitis Market Research and Analysis by End Users, 2025–2035 ($ Million)
35. Rest of the World Vasculitis Market Research and Analysis by Region, 2025–2035 ($ Million)
36. Rest of the World Vasculitis Market Research and Analysis by Type, 2025–2035 ($ Million)
37. Rest of the World Vasculitis Market Research and Analysis by Diagnosis Tests, 2025–2035 ($ Million)
38. Rest of the World Vasculitis Market Research and Analysis by Therapeutic Class, 2025–2035 ($ Million)
39. Rest of the World Vasculitis Market Research and Analysis by End Users, 2025–2035 ($ Million)
1. Global Vasculitis Market Share By Type, 2025 Vs 2035 (%)
2. Global Large Vessels Vasculitis Market Share By Region, 2025 Vs 2035 (%)
3. Global Medium Vessels Vasculitis Market Share By Region, 2025 Vs 2035 (%)
4. Global Small Vessels Vasculitis Market Share By Region, 2025 Vs 2035 (%)
5. Global Vasculitis Market Share By Diagnosis Tests, 2025 Vs 2035 (%)
6. Global Vasculitis Blood Test Market Share By Region, 2025 Vs 2035 (%)
7. Global Vasculitis Urine Test Market Share By Region, 2025 Vs 2035 (%)
8. Global Vasculitis Imaging Test Market Share By Region, 2025 Vs 2035 (%)
9. Global Vasculitis Other Diagnosis Tests Market Share By Region, 2025 Vs 2035 (%)
10. Global Vasculitis Market Share By Therapeutic Class, 2025 Vs 2035 (%)
11. Global Corticosteroids Vasculitis Market Share By Region, 2025 Vs 2035 (%)
12. Global Immunosuppressants Vasculitis Market Share By Region, 2025 Vs 2035 (%)
13. Global Biologics Vasculitis Market Share By Region, 2025 Vs 2035 (%)
14. Global Vasculitis Market Share By End Users, 2025 Vs 2035 (%)
15. Global Vasculitis For Hospitals and Clinics Market Share By Region, 2025 Vs 2035 (%)
16. Global Vasculitis For Diagnosis Center Market Share By Region, 2025 Vs 2035 (%)
17. Global Vasculitis For Research Institutes Market Share By Region, 2025 Vs 2035 (%)
18. Global Vasculitis For Other End Users Market Share By Region, 2025 Vs 2035 (%)
19. Global Vasculitis Market Share By Region, 2025 Vs 2035 (%)
20. US Vasculitis Market Size, 2025–2035 ($ Million)
21. Canada Vasculitis Market Size, 2025–2035 ($ Million)
22. UK Vasculitis Market Size, 2025–2035 ($ Million)
23. France Vasculitis Market Size, 2025–2035 ($ Million)
24. Germany Vasculitis Market Size, 2025–2035 ($ Million)
25. Italy Vasculitis Market Size, 2025–2035 ($ Million)
26. Spain Vasculitis Market Size, 2025–2035 ($ Million)
27. Russia Vasculitis Market Size, 2025–2035 ($ Million)
28. Rest of Europe Vasculitis Market Size, 2025–2035 ($ Million)
29. India Vasculitis Market Size, 2025–2035 ($ Million)
30. China Vasculitis Market Size, 2025–2035 ($ Million)
31. Japan Vasculitis Market Size, 2025–2035 ($ Million)
32. South Korea Vasculitis Market Size, 2025–2035 ($ Million)
33. Australia and New Zealand Vasculitis Market Size, 2025–2035 ($ Million)
34. ASEAN Economies Vasculitis Market Size, 2025–2035 ($ Million)
35. Rest of Asia-Pacific Vasculitis Market Size, 2025–2035 ($ Million)
36. Latin America Vasculitis Market Size, 2025–2035 ($ Million)
37. Middle East and Africa Vasculitis Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Vasculitis Market in 2025 is estimated to be around $293.2 million.
North America holds the largest share in the Vasculitis Market.
Leading players in the Vasculitis Market include Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline (GSK) plc, Novartis AG, and Pfizer Inc., among others.
Vasculitis Market is expected to grow at a CAGR of 4.4% from 2026 to 2035.
Rising prevalence of autoimmune and chronic diseases, increasing awareness, advancements in targeted therapies, and growing healthcare investments are driving Vasculitis Market growth.
